Cargando…

How the immune system responds to therapeutic biological agents

Biological agents target disease mechanisms and have modified the natural history of several immune-mediated disorders. Biological agents are structurally immunogenic, and therefore usually elicit a minor, subclinical and transient phenomenon. Occasionally, however, these drugs induce complete cellu...

Descripción completa

Detalles Bibliográficos
Autores principales:	Vultaggio, Alessandra, Petroni, Giulia, Pratesi, Sara, Nencini, Francesca, Cammelli, Daniele, Ferraro, Andrea, Maggi, Enrico, Matucci, Andrea
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2016
Materias:	Immuno-Mediated Diseases and Treatment Immunogenicity
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5536528/ https://www.ncbi.nlm.nih.gov/pubmed/27683137 http://dx.doi.org/10.1177/0300060515593248

Ejemplares similares

Long-term treatment with adalimumab in psoriatic arthritis: serum adalimumab concentration, immunogenicity and the link with clinical response
por: Chimenti, Maria Sole, et al.
Publicado: (2016)

Cardiovascular risk evaluation through heart rate variability analysis in psoriatic patients before and after 24 weeks of etanercept therapy: Prospective study
por: Potenza, Concetta, et al.
Publicado: (2016)

Serological markers associated with disease activity in patients with rheumatoid arthritis treated with rituximab
por: Conigliaro, Paola, et al.
Publicado: (2016)

Long-term safety of etanercept in psoriasis: Retrospective study focused on infections
por: Orsini, Diego, et al.
Publicado: (2016)

Treatment of psoriasis with etanercept in immunocompromised patients: Two case reports
por: De Simone, Clara, et al.
Publicado: (2016)

Suicide risk and psychiatric comorbidity in patients with psoriasis
por: Pompili, Maurizio, et al.
Publicado: (2016)

Influence of body mass index and weight on etanercept efficacy in patients with psoriasis: A retrospective study
por: Giunta, Alessandro, et al.
Publicado: (2016)

T Cell Response to Infliximab in Exposed Patients: A Longitudinal Analysis
por: Pratesi, Sara, et al.
Publicado: (2019)

Beneficial effects of long-term treatment with bosentan on the development of pulmonary arterial hypertension in patients with systemic sclerosis
por: Murdaca, Giuseppe, et al.
Publicado: (2016)

Post-translational modifications in rheumatoid arthritis and atherosclerosis: Focus on citrullination and carbamylation
por: Spinelli, Francesca Romana, et al.
Publicado: (2016)

Asymmetric dimethylarginine and arterial stiffness in patients with rheumatoid arthritis: A case–control study
por: Erre, Gian Luca, et al.
Publicado: (2016)

How to Prevent and Mitigate Hypersensitivity Reactions to Biologicals Induced by Anti-Drug Antibodies?
por: Vultaggio, Alessandra, et al.
Publicado: (2021)

Circulating T cells to infliximab are detectable mainly in treated patients developing anti‐drug antibodies and hypersensitivity reactions
por: Vultaggio, A., et al.
Publicado: (2016)

Asthma and Chronic Rhinosinusitis: How Similar Are They in Pathogenesis and Treatment Responses?
por: Matucci, Andrea, et al.
Publicado: (2021)

Strategies Targeting Type 2 Inflammation: From Monoclonal Antibodies to JAK-Inhibitors
por: Matucci, Andrea, et al.
Publicado: (2021)

Immune‐Related Adverse Events by Immune Checkpoint Inhibitors Significantly Predict Durable Efficacy Even in Responders with Advanced Non‐Small Cell Lung Cancer
por: Akamatsu, Hiroaki, et al.
Publicado: (2019)

Mechanisms of Drug Desensitization: Not Only Mast Cells
por: Vultaggio, Alessandra, et al.
Publicado: (2020)

Rapid clinical improvement of atopic dermatitis in an Omalizumab treated patient
por: Bormioli, Susanna, et al.
Publicado: (2019)

Efficacy and Safety of Mepolizumab (Anti-Interleukin-5) Treatment in Gleich’s Syndrome
por: Matucci, Andrea, et al.
Publicado: (2018)

Treatment with 8-OH-modified adenine (TLR7 ligand)-allergen conjugates decreases T helper type 2-oriented murine airway inflammation
por: Nencini, Francesca, et al.
Publicado: (2015)

Drug-specific Treg cells are induced during desensitization procedure for rituximab and tocilizumab in patients with anaphylaxis
por: Vultaggio, Alessandra, et al.
Publicado: (2021)

Ongoing Phase I Studies of Immune Checkpoint Inhibitors in China
por: Fang, Wenfeng, et al.
Publicado: (2019)

Combined Effect of Sarcopenia and Systemic Inflammation on Survival in Patients with Advanced Stage Cancer Treated with Immunotherapy
por: Bilen, Mehmet Asim, et al.
Publicado: (2019)

PD‐L1 Expression on Circulating Tumor Cells May Be Predictive of Response to Pembrolizumab in Advanced Melanoma: Results from a Pilot Study
por: Khattak, Muhammad A., et al.
Publicado: (2019)

Systematic Review of PD‐1/PD‐L1 Inhibitors in Oncology: From Personalized Medicine to Public Health
por: Chang, Elaine, et al.
Publicado: (2021)

The Inconsistent and Inadequate Reporting Of Immune‐Related Adverse Events in PD‐1/PD‐L1 Inhibitors: A Systematic Review of Randomized Controlled Clinical Trials
por: Xie, Tong, et al.
Publicado: (2021)

Humoral Immune Response of SARS‐CoV‐2–Infected Patients with Cancer: Influencing Factors and Mechanisms
por: Esperança‐Martins, Miguel, et al.
Publicado: (2021)

Analysis of Real‐World Data to Investigate the Impact of Race and Ethnicity on Response to Programmed Cell Death‐1 and Programmed Cell Death‐Ligand 1 Inhibitors in Advanced Non‐Small Cell Lung Cancers
por: Ayers, Kristin L., et al.
Publicado: (2021)

Safety of Immune Checkpoint Inhibitors in Patients with Cancer and Hepatitis C Virus Infection
por: Alkrekshi, Akram, et al.
Publicado: (2021)

Patient Blood Type Is Associated With Response to Immune Checkpoint Blockade in Metastatic Cancer
por: Chen, Ruifeng, et al.
Publicado: (2022)

Immune Checkpoint Inhibitors: The Unexplored Landscape of Geriatric Oncology
por: Choucair, Khalil, et al.
Publicado: (2022)

Safety and Clinical Activity of SHR7390 Monotherapy or Combined With Camrelizumab for Advanced Solid Tumor: Results From Two Phase I Trials
por: Wei, Xiao-Li, et al.
Publicado: (2022)

Phase II Trial of MEDI0457 and Durvalumab for Patients With Recurrent/Metastatic Human Papillomavirus-Associated Cancers
por: Morris, Van K, et al.
Publicado: (2023)

Evaluating Survival After Hospitalization Due to Immune-Related Adverse Events From Checkpoint Inhibitors
por: Silverstein, Jordyn, et al.
Publicado: (2023)

Identification of Immune Subtypes and Candidate mRNA Vaccine Antigens in Small Cell Lung Cancer
por: Wei, Yuanfeng, et al.
Publicado: (2023)

Safety and Efficacy of Immune Checkpoint Inhibitors in Patients with Cancer and Viral Hepatitis: The MD Anderson Cancer Center Experience
por: Nardo, Mirella, et al.
Publicado: (2023)

Characteristics of Immune Checkpoint Inhibitor-Associated Gastritis: Report from a Major Tertiary Care Center
por: Farha, Natalie, et al.
Publicado: (2023)

Association Between Rheumatic Autoantibodies and Immune-Related Adverse Events
por: Mathias, Kristen, et al.
Publicado: (2023)

Safety of Immune Checkpoint Inhibitors in Patients With Advanced Chronic Kidney Disease: A Retrospective Cohort Study
por: Tiu, Bruce C, et al.
Publicado: (2023)

Low-Dose Mepolizumab Effectiveness in Patients Suffering From Eosinophilic Granulomatosis With Polyangiitis
por: Vultaggio, Alessandra, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_259dnb1temic7d7ojtu2k4hmlm